Payment overview · 2025
General Payments
$1,110.38
59 reported records · 18 companies
Healthcare provider profile · identity verified
Sandhya Jain
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · DEARBORN, MI · NPI 1023500972
Verified facts
What the public records show
CMS Open Payments records show Sandhya Jain received $1,110.38 in general payments during 2025 across 59 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 31.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $351.36 | 31.6% | 26 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $267.44 | 24.1% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $92.58 | 8.3% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $54.37 | 4.9% | 3 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $46.03 | 4.2% | 2 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $39.29 | 3.5% | 2 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $34.90 | 3.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.35 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.71 | 2.7% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $26.85 | 2.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.15 | 1.8% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.61 | 1.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.77 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.62 | 1.5% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $16.42 | 1.5% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $16.33 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.28 | 1.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.32 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,110.38 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $351.36 | 26 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $267.44 | 8 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $239.90 | 7 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $92.58 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $46.03 | 2 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $39.29 | 2 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $34.90 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.35 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $16.42 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $16.33 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 149 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 89 | 30 |
| Omeprazole | Omeprazole | 88 | 30 |
| Lisinopril | Lisinopril | 71 | 31 |
| Trazodone Hcl | Trazodone Hcl | 68 | 24 |
| Levothyroxine Sodium | Levothyroxine Sodium | 64 | 22 |
| Gabapentin | Gabapentin | 55 | 22 |
| Metformin Hcl | Metformin Hcl | 54 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 29 |
| Sertraline Hcl | Sertraline Hcl | 49 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 39 | suppressed |
| Losartan Potassium | Losartan Potassium | 38 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 18 |
| Ibuprofen | Ibuprofen | 34 | 17 |
| Metformin Hcl Er | Metformin Hcl | 34 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 33 | 16 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Alprazolam | Alprazolam | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 31 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | 12 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | 11 |
| Metoprolol Succinate | Metoprolol Succinate | 27 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Mounjaro | Tirzepatide | 22 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 18 | suppressed |
| Prednisone | Prednisone | 17 | 14 |
| Furosemide | Furosemide | 16 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,110.38 · 59 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | ABRYSVO, ARISTADA, Auvelity, Azstarys, CAPLYTA, COMIRNATY, Cologuard Collection Kit, FANAPT, HETLIOZ, INGREZZA, LYBALVI, OPSUMIT, Ozempic, PREVNAR 20, Qelbree, Rybelsus, SPRAVATO, SUBLOCADE, The Cologuard Plus Collection Kit, UPTRAVI, VRAYLAR, XIFAXAN, YUPELRI, ZEPBOUND, ZURZUVAE | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error